Morgan Stanley on Ultragenyx Pharma (RARE): BLA submission acceptance removes key overhang

April 2, 2026 12:00 PM

Morgan Stanley analyst Maxwell Skor reiterated an Overweight rating and $50.00 price target on Ultragenyx Pharma (NASDAQ: RARE)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found